Boundless Bio (BOLD) Preferred Stock Liabilities (2023 - 2024)
Boundless Bio (BOLD) posted quarterly Preferred Stock Liabilities of $247.6 million for Q1 2024, up 67.37% year-over-year from $147.9 million in Q2 2023, and little changed quarter-over-quarter from $247.6 million in Q4 2023.
Boundless Bio (BOLD) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Boundless Bio (BOLD) has reported Preferred Stock Liabilities for 2 consecutive years, with $247.6 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Preferred Stock Liabilities rose 67.37% year-over-year to $247.6 million; the TTM figure through Mar 2024 stood at $247.6 million (up 67.37% YoY), while the FY2023 annual figure was $247.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $247.6 million in Q1 2024 per BOLD's latest filing, from $247.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $247.6 million in Q2 2023 and bottomed at $147.9 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | - |
| 10 | Boundless Bio | 67.57 Mn | 67.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 247.62 Mn |
| Dec 31, 2023 | 247.62 Mn |
| Sep 30, 2023 | 247.62 Mn |
| Jun 30, 2023 | 247.62 Mn |
| Mar 31, 2023 | 147.95 Mn |